No two compounds are paired in repair-pathway research as often as BPC-157 and TB-500 — and no two are conflated as often, either. They are structurally unrelated molecules studied through different mechanisms. Here is the side-by-side researchers actually need.
Two different molecules
| BPC-157 | TB-500 | |
|---|---|---|
| Origin | Fragment of a gastric protective protein | Actin-binding fragment of thymosin β4 |
| Length | 15 residues | 7 residues (Ac-LKKTETQ fragment) |
| Mass (approx.) | ~1,419.5 Da | ~890 Da |
| Research focus | Angiogenesis signaling, cytoprotection, tissue-repair pathways | Actin dynamics, cell migration, tissue remodeling |
| Stability reputation | Unusually stable for a peptide of its size | Robust short fragment |
Why they get studied together
Their mechanisms are complementary rather than overlapping: BPC-157 work centers on signaling and vascular pathways, while TB-500’s actin-binding biology concerns the cytoskeletal machinery of cell migration. Repair models involve both processes, which is why paired designs — and prepared dual research blends — are so common. The KLOW quad blend extends the same logic with GHK-Cu and KPV.
Choosing for a research design
- Signaling/vascular questions: BPC-157 designs dominate — see the full BPC-157 research overview.
- Migration/cytoskeleton questions: TB-500 — see the TB-500 overview, including the fragment-vs-full-length distinction that trips up sourcing.
- Combined models: paired dosing of separately verified lots, or a pre-made blend with a single COA covering both components.
Verification applies double
Two compounds means two identities and two purities to confirm. Whether sourced separately (BPC-157, TB-500) or as a blend, every Heartland lot publishes its certificate in the COA portal — ≥99% HPLC purity and mass-spec identity per component.
Both compounds are supplied strictly for in vitro laboratory research — not for human or veterinary use.